Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time

Thrombosis Research

Volumn 130, Issue 4, 2012, Pages 674-681

  Gudmundsdottir, Brynja R ^a   Francis, Charles W ^b   Bjornsdottir, Alexia M ^a   Nellbring, Moa ^a   Onundarson, Pall T ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; COUMARIN ANTICOAGULANT; PROTHROMBIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; FEMALE; FIBRIN FORMATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; ROTATIONAL THROMBOELASTOGRAPHY; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPHY;

ANTICOAGULANTS; BLOOD COAGULATION; FACTOR X; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PROTHROMBIN; PROTHROMBIN TIME; WARFARIN;

EID: 84866249075     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.12.013     Document Type: Article

References (31)

1. H.R. Roberts, and M.A. Escobar Other coagulation factor deficiencies J.S.A.I. Loscalzo, Thrombosis and Hemorrhage 3rd edn 2003 Lippincott Williams & Wilkins Philadelphia 575 598
2. M.C. van Dam-Mieras, and H.C. Hemker Half-life time and control frequency of vitamin K-dependent Coagulation factors. Theoretical considerations on the place of factor VII in the control of oral anticoagulation therapy Haemostasis 13 1983 201 208
3. A. Quick The prothrombin time in haemophilia and in obstructive jaundice J Bio Chem 109 1935 73 74
4. P.A. Owren, and K. Aas The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin Scand J Clin Lab Invest 3 1951 201 208
5. H.M. Haraldsson, P.T. Onundarson, K.A. Einarsdottir, B.R. Gudmundsdottir, M.K. Petursson, and K. Palsson Performance of prothrombin-proconvertin time as a monitoring test of oral anticoagulation therapy Am J Clin Pathol 107 1997 672 680
6. D.T. Le, R.T. Weibert, B.K. Sevilla, K.J. Donnelly, and S.I. Rapaport The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods Ann Intern Med 120 1994 552 558
7. A. Zivelin, L.V. Rao, and S.I. Rapaport Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors J Clin Invest 92 1993 2131 2140
8. M. Xi, S. Beguin, and H.C. Hemker The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients Thromb Haemost 62 1989 788 791
9. G. Mariani, A. Dolce, G. Marchetti, and F. Bernardi Clinical picture and management of congenital factor VII deficiency Haemophilia 10 2004 s180 s183
10. B. Furie, H.A. Liebman, R.A. Blanchard, M.S. Coleman, S.F. Kruger, and B.C. Furie Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy Blood 64 1984 445 451
11. B. Furie, C.F. Diuguid, M. Jacobs, D.L. Diuguid, and B.C. Furie Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy Blood 75 1990 344 349
12. A. Kornberg, C.W. Francis, V.D. Pellegrini Jr., K.R. Gabriel, and V.J. Marder Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis Circulation 88 1993 454 460
13. B. Sorensen, P. Johansen, K. Christiansen, M. Woelke, and J. Ingerslev Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation J Thromb Haemost 1 2003 551 558
14. J. Ingerslev, L.H. Poulsen, and B. Sorensen Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia Haemophilia 9 2003 348 352
15. C. Fenger-Eriksen, E. Anker-Moller, J. Heslop, J. Ingerslev, and B. Sorensen Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate Br J Anaesth 94 2005 324 329
16. E.A. Loeliger ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control Acta Haematol 72 1984 405 407
17. E.A. Loeliger, L. Poller, M. Samama, J.M. Thomson, A.M. Van den Besselaar, and J. Vermylen Questions and answers on prothrombin time standardisation in oral anticoagulant control Thromb Haemost 54 1985 515 517
18. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briet A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
19. K.E. Brummel, S.G. Paradis, R.F. Branda, and K.G. Mann Oral anticoagulation thresholds Circulation 104 2001 2311 2317
20. R. Luddington, C. Scales, and T. Baglin Lupus anticoagulant testing with optical end point automation Thromb Res 96 1999 197 203
21. M.D. Rand, and J.B. Lock van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood Blood 88 1996 3432 3445
22. H.G. Watson, and M. Greaves Can we predict bleeding? Semin Thromb Hemost 34 2008 97 103
23. M.T. Ganter, S. Schmuck, C.R. Hamiel, P.E. Wischmeyer, D. Heule, and A. Zollinger Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy J Cardiothorac Vasc Anesth 22 2008 675 680
24. L. Rugeri, A. Levrat, J.S. David, E. Delecroix, B. Floccard, and A. Gros Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography J Thromb Haemost 5 2007 289 295
25. C.M. Doran, T. Woolley, and M.J. Midwinter Feasibility of using rotational thromboelastometry to assess coagulation status of combat casualties in a deployed setting J Trauma 69 Suppl. 1 2010 S40 S48
26. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 160S 198S
27. D.M. Witt, T. Delate, N.P. Clark, C. Martell, T. Tran, and M.A. Crowther Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users J Thromb Haemost 8 2010 744 749
28. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and A.S. Gallus Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
29. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
30. H.C. Diener, S.J. Connolly, M.D. Ezekowitz, L. Wallentin, P.A. Reilly, and S. Yang Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial Lancet Neurol 9 2010 1157 1163
31. P.T. Onundarson, K.A. Einarsdottir, and B.R. Gudmundsdottir Warfarin anticoagulation intensity in specialist-based and in computer-assisted dosing practice Int J Lab Hematol 30 2008 382 389